.avif)
.avif)
Bicycle Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
Cambridge, England, UK
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing bicyclic peptide-based medicines to treat cancer and other diseases with operations in the UK and US.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@bicycletx.com
Company Overview
Industry
Biotechnology Research
Founded
2009
Headquarters
Cambridge, England, UK
Revenue
$25M-$50M
FUNDING Stage
Public
Key Executives
Kevin Lee (Chief Executive Officer), Travis Thompson (Chief Financial Officer), Jennifer Perry, Pharm.D. (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Bicycle Therapeutics?
Bicycle Therapeutics uses the first.last format on bicycletherapeutics.com, so Jane Smith would be jane.smith@bicycletherapeutics.com.
What cancer types does Bicycle Therapeutics focus on in its clinical pipeline?
Bicycle Therapeutics focuses exclusively on oncology, with clinical programs targeting cancers such as metastatic urothelial cancer and metastatic pancreatic ductal adenocarcinoma through its Bicycle Drug Conjugate and Bicycle Radioligand modalities.
How does the bicyclic peptide technology behind Bicycle Therapeutics work?
Bicycle Therapeutics builds its medicines on bicyclic peptide science pioneered by Sir Greg Winter and Professor Christian Heinis, using a proprietary phage display screening platform to create small, chemically synthesized molecules that can penetrate deep into tissues and bind tumor targets with high precision.
Who leads Bicycle Therapeutics and who are its senior executives?
Bicycle Therapeutics is led by Kevin Lee as Chief Executive Officer, alongside Travis Thompson as Chief Financial Officer and Jennifer Perry, Pharm.D., as Chief Operating Officer. You can use Clay to quickly surface and verify contact details for the leadership team.
Does Bicycle Therapeutics have any strategic partnerships with larger pharmaceutical companies?
Bicycle Therapeutics has a strategic collaboration with Bayer, signed in May 2023, to discover and develop novel targeted radioconjugates in oncology using Bicycle's proprietary phage display peptide platform, with potential deal value up to $1.7 billion.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating